Territorial Availability: Available through Bertin Technologies only in France
- Synonyms
- 6-(4-hydroxy-6-(methoxy-13C)-7-(methyl-13C)-3-oxo-1,3-dihydroisobenzofuran-5-yl-13C8)-4-(methyl-13C)hex-4-enoic-1,2,3,4,5,6-13C6 acid
- Correlated keywords
- GCMS LCMS Penicillium Candida Cryptococcus Staphylococcus CES 1 2
- Product Overview:
13C17-Mycophenolic acid is intended for use as an internal standard for the quantification of mycophenolic acid (Item No. 21716) by GC- or LC-MS. Mycophenolic acid is an immunosuppressive microbial metabolite that has been found in P. brevicompactum.{33309,33311} It is also an active metabolite of mycophenolate mofetil (Item No. 13988) that is formed via carboxylesterase 1 (CES1) and CES2.{57837} Mycophenolic acid is an inhibitor of IMP dehydrogenase (IMPDH) type I and type II (IC50s = 32 and 11 nM, respectively, in cell-free assays) and inhibits DNA synthesis in L strain mouse fibroblasts when used at concentrations ranging from 0.1 to 10 µg/ml.{21841,33310} It is active against several strains of C. albicans, C. parakrusei, C. tropicalis, and C. neoformans (MICs = 3.9-31.25 µg/ml), as well as various strains of S. aureus (MICs = 31.25-125 µg/ml).{33311} Mycophenolic acid (150 mg/kg) reduces splenomegaly in a mouse model of Friend virus-induced leukemia.{33313} It decreases the number of hemolytic plaque forming cells isolated from the spleen of mice immunized with sheep red blood cells (RBCs) when administered at doses ranging from 60 to 240 mg/kg.{33309} Formulations containing mycophenolic acid have been used as immunosuppressive agents in the prevention of organ transplant rejection.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.